Document |
Document Title |
WO/2024/092335A1 |
The present invention aims to solve the problems of the prior art by means of a new dermatological, pharmaceutical and/or cosmetic composition comprising sulphur derivatives, which is particularly useful for topical application before ra...
|
WO/2024/095232A1 |
A method of performing photodynamic therapy is provided. The method includes applying, to the skin of a patient, a topical composition. The topical composition includes 5- aminolevulinic acid (ALA) hydrochloride, and a vehicle comprising...
|
WO/2024/097641A2 |
The present disclosure relates to methods of treating a tumor in a subject in need thereof comprising administering an IL-27 inhibiting agent, wherein the subject is identified as having a tumor that (i) expresses WSX-1, (ii) comprises o...
|
WO/2024/095026A1 |
In the present invention azidation is used to render a molecule photoactivable and to influence its binding to its cognate specific binding partner in the eye. Thus, the invention relates to a compound for use in a method of treating a s...
|
WO/2024/096911A1 |
In some implementations, a device may include a therapy light source to produce a therapy light and a monitoring light source to produce a monitoring light. The device may include a light delivery fiber having a light delivery end and a ...
|
WO/2024/059715A3 |
The present invention provides methods for preparing acoustically-sensitive microbubbles. The method includes the steps of providing a first system comprising at least one water-soluble surfactant; providing a second system comprising at...
|
WO/2024/097997A2 |
The inventive technology is directed to novel photoacoustic endoskeletal droplet compositions and methods of making the same. Specifically, the naphthalocyanine dye-loaded endoskeletal droplets having a solid hydrocarbon core surrounded ...
|
WO/2024/091873A2 |
Disclosed herein are compositions comprising a small molecule that targets MTRES1. Also provided herein are methods of treating conditions associated with MTRES1 gene mutations that include providing a small molecule that targets MTRES1 ...
|
WO/2024/092181A2 |
Accordingly, the present invention relates to methods and systems for growing, expanding and/or obtaining human alveolar cells from one or both of induced-pluripotent stem cell (iPSC) derived tissue and bud tip progenitor cells derived f...
|
WO/2024/086692A2 |
The present disclosure relates to compositions and methods for the treatment of neurological disorders.
|
WO/2024/086724A2 |
Methods for decreasing or inhibiting herpesviridae infection, or associated condition, disease, or pathogenesis or other adverse effect of herpesviridae infection including reactivation of herpesviridae in a subject by administering to t...
|
WO/2024/086533A2 |
The present disclosure provides methods for treating or preventing neuroendocrine tumor formation in subjects diagnosed with TP53 and RBI deficient adenocarcinomas (e.g., lung or prostate adenocarcinomas) using CDC7 inhibitors. Also disc...
|
WO/2024/085525A1 |
The present invention relates to an iridium complex, a photosensitizer, and a composition for photodynamic therapy and to an iridium complex, a photosensitizer, and a composition for photodynamic therapy wherein the iridium complex is po...
|
WO/2024/084096A1 |
The present invention relates to novel photosensitive diazirine-conjugated phospholipids, and their use in delivering and releasing an active ingredient in a controlled manner, as well as photosensitive liposomes and controlled delivery ...
|
WO/2024/083937A2 |
The present invention relates to a method for imaging an anatomical structure in a subject in need thereof, comprising the following steps: a) providing an injectable pharmaceutical composition comprising, as a contrast agent, at least o...
|
WO/2024/086581A2 |
This invention provides methods to determine the stage in the natural time course of immune response in a subject. It describes method to control immune response by targeting regulatory mechanisms differentially operating in lymphocytes ...
|
WO/2024/086708A2 |
Disclosed herein are small molecule inhibitors of USP30 and their use in treating, ameliorating and/or preventing cardiomyopathy. Additionally, disclosed herein are methods of inhibiting the USP30 pathway and activity comprising contacti...
|
WO/2024/086562A2 |
The present disclosure provides methods for treating or preventing neuroendocrine tumor formation in subjects diagnosed with TP53 and RBI deficient adenocarcinomas (e.g., lung or prostate adenocarcinomas) using XP01 inhibitors. Also disc...
|
WO/2024/081428A2 |
Biologically active AhR ligand compounds, and pharmaceutical combinations comprising such compounds, tor treating proliferative cell diseases, such as cancer. Therapeutic combinations also are disclosed that comprise at least one AhR lig...
|
WO/2024/081688A2 |
The present disclosed and described technology are directed to multimodal mRNA-based immunotherapies that deliver both antigens and immunomodulators. Related formulations, method of administration, and kits are disclosed and described.
|
WO/2024/081928A1 |
The present invention relates to a hemoglobin protein composition comprising biologically active hemoglobin and less than 2% methemoglobin (metHb) wherein the metHb is maintained below 2% after reoxygenation of hemoglobin. Furthermore, h...
|
WO/2024/077224A2 |
The present invention relates to compositions and methods for preventing or treating diseases or disorders involving nucleic acid damage, such as cancer, in a subject, as well as methods of identifying gut microbes, strains or metabolite...
|
WO/2024/077155A1 |
The present invention provides a method of delivering a tumor-targeting bacterium to a tumor site in an individual having cancer, comprising orally administering to the individual an effective amount of the tumor-targeting bacterium or b...
|
WO/2024/077297A2 |
Provided are methods of administering a peptide antagonist of CCAAT/enhancer-binding protein beta (C/EBPβ) in combination with an immunomodulating agent.
|
WO/2024/075089A1 |
The present invention discloses a hybrid metal-lipid nanoparticle for targeted therapy comprising properties of organic and inorganic nanoparticles (NPs), combined in a single formulation to obtain NPs with unique attributes. This will a...
|
WO/2024/076245A1 |
The invention provides a method of enhanced ultrasound ablation and a composition for the use thereof. The method comprises: creating at least one ablation-assisting bubble proximate to a target region by: administering a cluster composi...
|
WO/2024/077106A2 |
Disclosed are methods for treating infectious diseases and cancers comprising administering to a subject a L-fucose.
|
WO/2024/077042A2 |
A method for treating a neutrophilic lung disease in a human subject in need thereof is disclosed, including administering a pharmaceutical composition including an effective amount of an IL-IRa (e.g., rhIL-1Ra) to the human subject, whe...
|
WO/2024/077130A1 |
The present disclosure relates to compositions and methods for treating bladder cancer. In some embodiments the compositions and methods involve using antisense (AS) nucleic acids directed against Insulin-like Growth Factor 1 Receptor (I...
|
WO/2024/077286A2 |
Compositions and methods are described herein that are useful for the detection of prostate cancer progression by determining the expression levels of genes associated with metastatic PCa. Based on the expression of IL-6, SELE, FOSB, NRK...
|
WO/2024/077264A2 |
The present disclosure provides methods for treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of a GPX4 inhibitor and a PARP inhibitor, wherein the subject is BRCA1 deficient (e.g., ...
|
WO/2024/068100A1 |
Metal based nanoparticles coated with a polymer functionalized with thiol groups and 5 -NH groups, said polymer preferably being selected among thiolated chitosan, thiolated and aminated alginic acid, thiolated and aminated hyaluronic ac...
|
WO/2024/071530A1 |
The present invention relates to fluorescent nanodiamond coated with porous polydopamine, a method for preparing the fluorescent nanodiamond, and novel use of the fluorescent nanodiamond. The fluorescent nanodiamond coated with porous po...
|
WO/2024/064766A2 |
As described below, the present invention features compositions, panels of biomarkers, and methods for selecting a subject with chronic lymphocytic leukemia (CLL) for treatment using an agent and/or for inclusion in a clinical trial usin...
|
WO/2024/064807A2 |
Methods of treatment of medulloblastoma by administering thyroid hormone (T3) to a subject are provided herein.
|
WO/2024/064898A2 |
Compositions and methods for treating cutaneous radiation injury (CRI), including radiation dermatitis, radiation proctopathy, or oral mucositis, employing one or more functional inhibitor of acid sphingomyelinase (FIASMA).
|
WO/2024/064879A2 |
Provided herein are methods for treating inflammatory diseases, such as inflammatory bowel disease (IBD), by administering to a subject an agent to inhibit interferon lambda (IFNL) signaling in intestinal epithelial cells. Such methods m...
|
WO/2024/063095A1 |
The prevent invention provides a radiolabeled tyrosine derivative which has excellent LAT1 selectability, higher retention at a tumor or cancer site, and a degree of clearance that does not cause side effects, and which can be safely man...
|
WO/2024/064255A2 |
Disclosed are methods for identifying and treating a subject having obstructive sleep apnea.
|
WO/2024/064964A2 |
Described herein are methods of inducing proliferation of PRX1 expressing stem cells stem cells in a subject in need thereof, the method can include administering an effective amount of niclosamide, or a pharmaceutically acceptable salt,...
|
WO/2024/064749A2 |
A composition, method of making, and method of using an active agent against a myriad of known as well as unknown pathogens comprising: binding a live influenza virus with a neuraminidase inhibitor in vitro; and administering the active ...
|
WO/2024/059820A2 |
The present disclosure provides methods for restoring regulatory T cell (Treg) function. Methods of treating a disease (e.g., an autoimmune disease or a cancer) in a subject in need thereof are also disclosed. The present disclosure furt...
|
WO/2024/059654A2 |
This disclosure relates to compositions and methods for treating type 1 diabetes.
|
WO/2024/059834A2 |
Chimeric antigen receptor (CAR) T cell therapies have revolutionized the treatment of B cell malignancies, but a significant proportion of patients with large B cell lymphoma (LBCL) experience primary resistance or relapse after CAR T ce...
|
WO/2024/057156A1 |
A composition for making a model for simulating soft tissue using ICG ( indiocyanine green) type fluorescence, comprising a material in particle form suitable for emitting a fluorescence in the near infrared and comprising calcium oxide ...
|
WO/2024/059688A2 |
The present disclosure provides compositions, methods, kits and uses for regulating blood-Central Nervous System (blood-CNS) barrier permeability (e.g., increasing or decreasing blood-CNS barrier permeability) by regulating signaling bet...
|
WO/2024/059549A2 |
A novel 3-marker microbial-related metabolite panel (3MMP), consisting of or comprising TMAO, indoleacrylic acid, and an indole derivative, and a novel 5-marker non-microbial metabolite panel, consisting of or comprising cholesterol gluc...
|
WO/2024/059757A2 |
Disclosed are methods and compositions related to reviving the functionality for exhausted T cells and methods of improving immunotherapy by inhibiting T cell exhaustion. In one aspect, the methods and compositions described herein compr...
|
WO/2024/059480A2 |
The present invention provides a method for improving glycemic control in a patient in need thereof, comprising administering to said patient, tirzepatide, or a pharmaceutically acceptable salt thereof, wherein said patient has failed to...
|
WO/2024/059878A2 |
A method to treat cancer using compounds that perform combinatorial targeting of the telomerase and the RNA-dependent RNA polymerase activity of TERT.
|